Status:
COMPLETED
Airway Epithelium Gene Expression: AEGIS IDE
Lead Sponsor:
Allegro Diagnostics, Corp.
Collaborating Sponsors:
University of Pennsylvania
Columbia University
Conditions:
Lung Cancer
Eligibility:
All Genders
21+ years
Brief Summary
The purpose of the research study is to develop a new, more sensitive, and less invasive test for diagnosing lung cancer at an earlier stage, when it can more easily be cured. The investigators hypoth...
Detailed Description
Allegro Diagnostics is funding this multi-center study to validate and extend a new diagnostic tool measuring global gene expression in airway epithelial cells obtained at routine bronchoscopy in susp...
Eligibility Criteria
Inclusion
- Patients being evaluated for the diagnosis of possible lung cancer or "rule out lung cancer" and undergoing clinically indicated bronchoscopy
- All patients are required to be at least 21 years of age and be able to understand and sign the informed consent form
- Patient must be a current or former cigarette smoker
Exclusion
- A pulmonary physician does not recommend that bronchoscopy be performed
- Inability to understand the written consent form and comply with requirements of the study
- History of prior primary lung cancer
- Immediately prior to bronchoscopy, the patient has been on a mechanical ventilator for \>24 consecutive hours.
Key Trial Info
Start Date :
February 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2015
Estimated Enrollment :
1331 Patients enrolled
Trial Details
Trial ID
NCT00746759
Start Date
February 1 2010
End Date
February 1 2015
Last Update
June 4 2015
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama
Birmingham, Alabama, United States, 35294
2
Pulmonary Associates of Arizona
Phoenix, Arizona, United States, 85006
3
University of California- Davis
Sacramento, California, United States
4
National Jewish Health
Denver, Colorado, United States, 80206